PMID- 32210617
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240328
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 12
DP  - 2020
TI  - Impact of the Activation Status of the Akt/mTOR Signalling Pathway on the 
      Clinical Behaviour of Synovial Sarcoma: Retrospective Analysis of 174 Patients at 
      a Single Institution.
PG  - 1759-1769
LID - 10.2147/CMAR.S228578 [doi]
AB  - PURPOSE: Phosphoinositide 3-kinase (PI3K) and the downstream Akt/mammalian target 
      of rapamycin (mTOR) pathway are central to the control of cell proliferation and 
      survival. Although abnormal activation of this pathway has been well established 
      in a variety of tumours, limited studies are available on synovial sarcoma. The 
      aim of this study was to investigate the expression of several key proteins of 
      those pathways in synovial sarcomas and to correlate the expression of these 
      proteins with clinicopathologic features and prognosis. PATIENTS AND METHODS: A 
      total of 174 patients with synovial sarcomas were recruited for this study. The 
      phosphorylation status of Akt, mTOR, and eukaryotic translation initiation factor 
      4E binding protein (4E-BP1) was measured by immunohistochemistry assays in 
      formalin-fixed, paraffin-embedded samples. Correlations between the expression 
      levels of these proteins and clinicopathologic features and prognosis were 
      analysed. RESULTS: The positive rates of phosphorylated (p)Akt, pmTOR, p4E-BP1, 
      and CyclinD1 were 62.7%, 55.6%, 47.1%, and 52.6%, respectively. The positive 
      results of pmTOR, pAkt, and downstream p4E-BP1 were correlated with each other. 
      The positive pAkt, pmTOR, p4E-BP1, and CyclinD1 results were more highly 
      expressed in head and neck and visceral tumours, and positive p4E-BP1 results 
      were correlated with larger size and larger areas of necrosis. In multivariate 
      analysis of clinicopathologic factors, head and neck and visceral location, large 
      tumour size, larger areas of necrosis and frequent mitosis were confirmed as risk 
      factors for shorter overall survival. Positive pAkt, pmTOR and p4E-BP1 results 
      were correlated significantly with shorter overall survival, and CyclinD1 was not 
      in the univariate analysis. The positive pmTOR, pAkt, p4E-BP1, and CyclinD1 
      results were significantly poor prognostic factors for overall survival, and only 
      positive p4E-BP1 results were significantly associated with shorter event-free 
      survival in multivariate analysis. CONCLUSION: This study demonstrated the high 
      expression of pAkt, pmTOR, and p4E-BP1 associated with aggressive clinical 
      behaviour in synovial sarcomas and provided evidence for prognostic evaluation 
      and targeted therapy.
CI  - (c) 2020 Li et al.
FAU - Li, Ying-Xue
AU  - Li YX
AD  - Department of Pathology, Medical School of Chinese People's Liberation Army, 
      Beijing 100853, People's Republic of China.
AD  - Department of Pathology, Liaocheng People's Hospital, Liaocheng 252000, Shandong, 
      People's Republic of China.
FAU - Ding, Shan-Shan
AU  - Ding SS
AD  - Department of Pathology, PLA Rocket Force Characteristic Medical Center, Beijing 
      100032, People's Republic of China.
FAU - Wen, Wen-Juan
AU  - Wen WJ
AD  - Department of Pathology, Liaocheng People's Hospital, Liaocheng 252000, Shandong, 
      People's Republic of China.
FAU - Han, Lin
AU  - Han L
AD  - Department of Pathology, Liaocheng People's Hospital, Liaocheng 252000, Shandong, 
      People's Republic of China.
FAU - Wang, Hong-Qun
AU  - Wang HQ
AUID- ORCID: 0000-0003-2791-6345
AD  - Department of Pathology, Medical School of Chinese People's Liberation Army, 
      Beijing 100853, People's Republic of China.
FAU - Shi, Huai-Yin
AU  - Shi HY
AD  - Department of Pathology, Medical School of Chinese People's Liberation Army, 
      Beijing 100853, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20200309
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC7074818
OTO - NOTNLM
OT  - clinicopathologic features
OT  - p4E-BP1
OT  - pAkt
OT  - pmTOR
OT  - prognosis
OT  - synovial sarcoma
COIS- The authors report no conflicts of interest related to this work.
EDAT- 2020/03/27 06:00
MHDA- 2020/03/27 06:01
PMCR- 2020/03/09
CRDT- 2020/03/27 06:00
PHST- 2019/08/24 00:00 [received]
PHST- 2020/02/08 00:00 [accepted]
PHST- 2020/03/27 06:00 [entrez]
PHST- 2020/03/27 06:00 [pubmed]
PHST- 2020/03/27 06:01 [medline]
PHST- 2020/03/09 00:00 [pmc-release]
AID - 228578 [pii]
AID - 10.2147/CMAR.S228578 [doi]
PST - epublish
SO  - Cancer Manag Res. 2020 Mar 9;12:1759-1769. doi: 10.2147/CMAR.S228578. eCollection 
      2020.